Amgen Sues Apotex to Block Otezla Copies as Appeals Pend (1)

Amgen Inc. alleges that generic versions of Otezla proposed by Apotex Inc. infringe three patents for the blockbuster arthritis drug, including two that are the subjects of pending appeals of a September ruling that could block copies until early 2028, according to a federal lawsuit in New Jersey.

Amgen on Sept. 20 won a federal court ruling that could block copycats proposed by Zydus Lifesciences Ltd. and Novartis AG’s Sandoz Inc. until February 2028. A New Jersey judge found Zydus and Sandoz infringe one patent and upheld its validity. He canceled three claims of another patent, finding they cover ...